Martin Shkreli ordered to return $64 million, is barred from drug industry squib

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015.
Continue reading on The Hindu...
Tags: